Company research
NEXUS BIOPHARMA INC
CIK 1424151Updated Sep 25, 2026
Securities
Historical securities (1)
NEXS · NASDAQ · equity · closed Jun 25, 2021Name history
Plata Resources, Inc. · through May 18, 2016
NEXS price & chart
Historical security
This listing closed Jun 25, 2021. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2017 · USDSource
Source
Source
balance sheet · annual statements
| Line item | FY 2017 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 9,527Source | 0Source | 5,000Source | 0Source |
| Property, Plant and Equipment, NetUSD | 1,575Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 6,875Source | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 77Source | — | — | — |
| Assets, CurrentUSD | 1,077Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,463,340Source | 85,417Source | — | — |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 64,310Source | — | — | — |
| Additional Paid in CapitalUSD | 1,776,324Source | 41,900Source | 41,900Source | 41,900Source |
| Retained Earnings (Accumulated Deficit)USD | -3,294,447Source | -191,117Source | -149,271Source | -147,871Source |
| Stockholders' Equity Attributable to ParentUSD | — | -85,417Source | -43,571Source | -42,171Source |
| Liabilities and EquityUSD | 9,527Source | 0Source | 5,000Source | 0Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,415,561Source | — | 48,571Source | 42,171Source |
| Accounts Payable, CurrentUSD | 200,000Source | 25,947Source | 16,230Source | 21,506Source |
cash flow · annual statements
| Line item | FY 2017 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,489Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 91,800Source | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | — | 9,717Source | -5,276Source | 11,392Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | -369Source |
| Additional Financial Items | ||||
| AmortizationUSD | 6,668Source | — | — | — |
| General and Administrative ExpenseUSD | 623,683Source | 41,846Source | 1,400Source | 15,261Source |
| Net Income (Loss) Attributable to ParentUSD | -686,100Source | -41,846Source | -1,400Source | -15,261Source |
| Operating Costs and ExpensesUSD | — | 41,846Source | 1,400Source | 15,261Source |
| Operating ExpensesUSD | 655,087Source | — | — | — |
income statement · annual statements
| Line item | FY 2017 | FY 2012 | FY 2011 |
|---|---|---|---|
| Net Income (Loss) Attributable to ParentUSD | -686,100Source | -9,376Source | -15,329Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 191,400,000Source | 191,400,000Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 623,683Source | 16,368Source | 15,329Source |
| Interest Income (Expense), NetUSD | -31,013Source | — | — |
| Operating Costs and ExpensesUSD | — | 16,368Source | — |
| Operating ExpensesUSD | 655,087Source | — | — |
| Research and Development ExpenseUSD | 31,404Source | — | — |